Acumen Pharmaceuticals Inc (ABOS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.22-7.72%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ABOS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
ABOS — workforce reduction
Dated 2026-11-05
of Form 8-K, the Company will file an amendment to this Current Report on Form 8-K once it makes a determination of such estimates or range of estimates. The Company may also incur other charges or cash expenditures not currently contemplated in connection with the Restructuring. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements. Any statement describing the Company’s goals, expectations, financial or other projections, intentions or beliefs is a f…
Why it matters: Acumen plans to stop sabirnetug and explore strategic options. A named deal or clear plan would show what comes next.
Watch forAcumen names a buyer, partner, or clear plan for its EBD program in a company release or SEC filing.
Also watch forAcumen reports no deal or plan, or says it will wind down the EBD program.
Why it matters: Acumen had $78.6 million in cash and securities at September 30. It said this could fund current work into early 2027.
Worry ifA company update puts cash and securities below $78.6 million before early 2027. It names no new funding or deal.
Less concerning ifAcumen reports at least $78.6 million in cash and securities. Or it names new funding to cover current work into early 2027.
Why it matters: The EBD program is a stated next step after Acumen plans to stop sabirnetug. An IND filing would mark a move toward human testing.
Supportive ifAcumen files an IND for an EBD lead candidate by mid-2027 and names the candidate.
Worry ifAcumen delays the IND past mid-2027, drops the lead candidate, or reports no active EBD development.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$264 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $776 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,377 loss on $10,000 · 93.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.